

Media Release

Zug, 28 May 2021

HBM portfolio company Swixx BioPharma announces EUR 45 million capital increase

Swixx BioPharma, a privately held company in the portfolio of HBM Healthcare Investments, today announced the signing of an investment agreement with Mérieux Equity Partners and its existing shareholders. Under the terms of the agreement, Mérieux Equity Partners will invest EUR 40 million for a minority stake in Swixx. HBM Healthcare Investments, who is an investor in Swixx since 2017, participates with EUR 5 million in the capital increase. The financing is subject to routine regulatory approvals and is expected to close in the next few months. The new capital will be used to leverage the steady growth that Swixx has enjoyed over the past few years. Mérieux Equity Partners and HBM Healthcare Investments have arrangements in place to further increase their investment in Swixx based upon the realisation of certain milestones.

In accordance with its valuation principles, HBM Healthcare Investments will revalue its investment in Swixx to reflect the equity valuation underlying to this capital increase. As a result, the net asset value per HBM-share increases by approximately 2 per cent.

Founded in Switzerland in 2014 by Petr Němec and Stuart Swanson, Swixx BioPharma is a specialized distributor of rare diseases, Rx and OTC medicinal products in Central & Eastern Europe, and acts as a true commercialization partner for pharma and biotech companies in this area. It aims to fully replace its partners capabilities in countries that multinationals choose not to enter, or to exit. With 550+ employees, Swixx BioPharma is the largest agent for ethical pharmaceuticals serving research-based biopharma in CEE and has experienced exceptional growth over the last few years, from less than EUR 50 million in revenues in 2017 to EUR 230 million in net sales in 2020. Its clients include international pharma and biotech companies such as Bristol-Myers Squibb, Amgen, Seattle Genetics, Y-mabs, Alexion, Jazz Pharmaceuticals, UPSA, Vifor Pharma, HRA Pharma and others.

Contact

For further information, please contact Dr. Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their

HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Phone: +41 41 710 75 77 | info@hbmhealthcare.com | www.hbmhealthcare.com

Follow us on Twitter: [@HbmHealthcare](https://twitter.com/HbmHealthcare)

strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to US persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments AG's securities were not issued in accordance with the U.S. U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions.